BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF) (TSX VENTURE:IXS) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™), announced today that it has received notices of allowance on several of its patent applications both in the United States Patent & Trademark Office (USPTO) and in the European Patent Office (EPO) covering its DXL™ technology.
